Business Context and Reporting Period
Company: Phibro Animal Health Corporation (PAHC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2026
Business Overview: A global diversified animal health and mineral nutrition company marketing approximately 790 product lines in 90 countries. The company operates three segments: Animal Health, Mineral Nutrition, and Performance Products. A significant strategic event during the period was the October 31, 2024, acquisition of Zoetis Inc.'s medicated feed additive (MFA) portfolio for approximately $297.5 million, which contributed $358.2 million to net sales in fiscal 2026.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Net Sales | $1,518.1 million | $1,296.2 million | +17% |
| Gross Profit | $512.5 million | $399.9 million | +28% |
| Gross Margin | 33.8% | 30.9% | +290 bps |
| Operating Income | $194.4 million | $110.5 million | +76% |
| Net Income | $99.7 million | $48.3 million | +107% |
| Diluted EPS | $2.43 | $1.19 | +104% |
| Adjusted EBITDA | $255.0 million | $183.7 million | +39% |
| Operating Cash Flow | $69.0 million | $80.1 million | -14% |
| Total Debt (Principal) | $737.9 million | $738.1 million | Flat |
| Working Capital | $562.1 million | $456.3 million | +23% |
Note: Debt figures reflect principal amounts. Total indebtedness includes $621.9 million in term loans and $116.0 million in revolver borrowings as of June 30, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% year-over-year, driven primarily by the Animal Health segment (+21%). The Animal Health growth was fueled by $146.1 million in incremental revenue from the Zoetis MFA acquisition, alongside increased demand for legacy products in Mexico and Southeast Asia.
- Profitability Expansion: Operating income surged 76% to $194.4 million. Gross margin expanded 290 basis points to 33.8%, attributed to favorable product mix, price increases, and the absence of prior-year inventory write-offs ($3.8 million in FY2025).
- Expense Management: Selling, General, and Administrative (SG&A) expenses rose 10% to $318.1 million. This increase included $8.6 million in costs for the "Phibro Forward" growth initiative and higher employee-related costs due to the acquisition. However, acquisition-related transaction costs decreased significantly from $13.3 million in FY2025 to $1.3 million in FY2026.
- Interest Expense: Net interest expense increased 28% to $44.4 million due to higher average term loan balances financing the acquisition and the expiration of a favorable interest rate swap agreement.
- Foreign Currency: Net foreign currency losses increased to $12.6 million (from $7.9 million), driven by fluctuations in the Israeli New Shekel, Argentine Peso, and Euro.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management expects global demand for animal protein to remain strong, driven by population growth. The company is focused on integrating the Zoetis acquisition, expanding vaccine production capacity in Ireland and Brazil, and advancing the "Phibro Forward" initiative to unlock cost savings and revenue growth. A quarterly dividend of $0.12 per share was declared on July 28, 2026.
Strategic Initiatives and Unusual Items
- Facility Closure: In August 2026, management decided to close the Chicago Heights, Illinois manufacturing facility, with production shutdown expected in summer 2027. Financial impacts are currently being evaluated.
- Tariff Recovery: Following a Supreme Court ruling in February 2026, the company is pursuing the recovery of approximately $11.7 million in previously paid IEEPA tariffs. Claims have been accepted by U.S. Customs and Border Protection.
- Regulatory Challenges:
- Carbadox (Mecadox): The FDA revoked the approved method for detecting carbadox residues in November 2023 and proposed withdrawing approval. Phibro is defending the product in court. Sales were approximately $21 million in FY2026.
- Brazil Regulations: In April 2026, Brazil's MAPA prohibited the use of virginiamycin for performance enhancement, with an 180-day transition period. Phibro is seeking therapeutic indications for the product. Sales in Brazil were approximately $27 million in FY2026.
Risk Factors
- Geopolitical Instability: Ongoing conflicts in the Middle East (Israel) and between Russia and Ukraine pose risks to operations, supply chains, and logistics. Israeli operations account for 16% of consolidated net sales.
- Regulatory Restrictions: Continued global scrutiny on the use of medically important antimicrobials (MIAs) and potential bans on specific products (e.g., carbadox, virginiamycin) could materially impact sales.
- Debt Service: Substantial indebtedness ($737.9 million principal) requires significant cash flow for interest and principal payments, limiting financial flexibility.
- Animal Disease Outbreaks: Outbreaks such as African Swine Fever or Avian Influenza could reduce demand for animal protein and, consequently, the company's products.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and revenue growth from the Zoetis MFA portfolio beyond the initial ramp-up period.
- Regulatory Status of Key Products: Monitor the outcome of the FDA litigation regarding carbadox (Mecadox) and the progress of therapeutic registration for virginiamycin in Brazil.
- Debt Covenants: Confirm continued compliance with the Amended 2024 Credit Agreement covenants, specifically the Net Leverage Ratio and Interest Coverage Ratio.
- Facility Closure Costs: Track the financial impact and timeline of the Chicago Heights facility closure announced in August 2026.
- Tariff Refund Realization: Confirm the actual receipt of the $11.7 million in tariff refunds from U.S. Customs.
- Geopolitical Exposure: Assess the operational continuity of manufacturing sites in Israel amidst ongoing regional conflicts.